Hamdy Ahmed MD 4

What Happened

• Hamdy Ahmed, M.D., Chief Medical Officer of Curis, Inc. (CRIS), was reported as receiving four equity awards/other acquisitions on March 17, 2026: one grant of 50 derivative shares and three grants of 66,667 derivative shares (total = 200,051 derivative shares). The Form 4 lists these as awards/acquisitions (code A) with no per-share cash price reported on the face of the form.
• Footnotes clarify these securities involve Series B Convertible Preferred Stock and attached Series A, B and C warrants. Each purchased “Security” was sold at $1,000 per Security to the reporting person (footnote F2). The Series B preferred stock automatically converts into common stock at 1,333.33 common shares per preferred share at 5:00 p.m. ET on March 20, 2026 (subject to limits) (footnote F1).

Key Details

• Transaction date: March 17, 2026; Form filed March 18, 2026 (timely).
• Reported grants: 50; 66,667; 66,667; 66,667 — total 200,051 derivative shares.
• Price on Form 4: N/A. Footnote F2: each Security was sold at $1,000 per Security to the reporting person.
• Conversion/exercise notes:
  • Series B Preferred converts to 1,333.33 common shares per preferred on March 20, 2026 (F1).
  • Series A and Series C warrants became immediately exercisable on March 17, 2026 (F3, F5).
  • Series B warrants are immediately exercisable but have special termination and potential exercise-price reset tied to a clinical milestone (F4).
• Shares owned after transaction: not disclosed in the supplied summary of the filing.

Context

• These entries report derivative acquisitions/awards rather than an open-market purchase or sale of common stock. For retail investors, the key points are the imminent conversion feature (potentially large increase in common shares if conversion occurs) and the attached warrants with varying exercisability and termination terms.
• This is an award/acquisition filing (not a sale). The filing appears timely (filed the next day). As always, derivative awards and automatic conversions can dilute existing holders and should be considered alongside company disclosures about conversion mechanics and beneficial ownership limits.